Work

A phase I dose escalation study with anti-CD44V6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus

Year: 2007

Type: article

Source: Radiotherapy and Oncology

DOI: 10.1016/s0167-8140(07)80090-9

Authors: R. De Bree, B.M. Tijink, J. Buter, G. Giaccone, M.S. Lang, A. Staab, C.R. Leemans, G.A.M.S. Van Dongen

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2004032375

FWCI:

Cites:

Cited by: 3

Related to: 10